Lee C, Kang H S, Chung J K, Sekiya F, Kim J R, Han J S, Kim S R, Bae Y S, Morris A J, Rhee S G
Laboratory of Cell Signaling, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-0320, USA.
J Biol Chem. 1997 Jun 20;272(25):15986-92. doi: 10.1074/jbc.272.25.15986.
In the accompanying paper (Chung, J.-K., Sekiya, F., Kang, H.-S., Lee, C., Han, J.-S., Kim, S. R., Bae, Y. S., Morris, A. J., and Rhee, S. G. (1997) J. Biol. Chem. 272, 15980-15985), synaptojanin is identified as a protein that inhibits phospholipase D (PLD) activity stimulated by ADP-ribosylation factor and phosphatidylinositol 4, 5-bisphosphate (PI(4,5)P2). Here, the purification from rat brain cytosol of another PLD-inhibitory protein that is immunologically distinct from synaptojanin is described, and this protein is identified as clathrin assembly protein 3 (AP3) by peptide sequencing and immunoblot analysis. AP3 binds both inositol hexakisphosphate and preassembled clathrin cages with high affinity. However, neither inositol hexakisphosphate binding nor clathrin cage binding affected the ability of AP3 to inhibit PLD. AP3 also binds to PI(4,5)P2 with low affinity. But the PI(4,5)P2 binding was not responsible for PLD inhibition, because the potency and efficacy of AP3 as an inhibitor of PLD were similar in the absence and presence of PI(4,5)P2. A bacterially expressed fusion protein, glutathione S-transferase-AP3 (GST-AP3), also inhibited PLD with a potency equal to that of brain AP3. The inhibitory effect of AP3 appeared to be the result of direct interaction between AP3 and PLD because PLD bound GST-AP3 in an in vitro binding assay. Using GST fusion proteins containing various AP3 sequences, we found that the sequence extending from residues Pro-290 to Lys-320 of AP3 is critical for both inhibition of and binding to PLD. The fact that AP3 is a synapse-specific protein indicates that the AP3-dependent inhibition of PLD might play a regulatory role that is restricted to the rapid cycling of synaptic vesicles.
在随附论文(Chung, J.-K., Sekiya, F., Kang, H.-S., Lee, C., Han, J.-S., Kim, S. R., Bae, Y. S., Morris, A. J., and Rhee, S. G. (1997) J. Biol. Chem. 272, 15980 - 15985)中,突触素被鉴定为一种抑制由ADP - 核糖基化因子和磷脂酰肌醇4,5 - 二磷酸(PI(4,5)P2)刺激的磷脂酶D(PLD)活性的蛋白质。在此,描述了从大鼠脑细胞质中纯化另一种与突触素在免疫学上不同的PLD抑制蛋白,并且通过肽测序和免疫印迹分析将该蛋白鉴定为网格蛋白组装蛋白3(AP3)。AP3以高亲和力结合肌醇六磷酸和预组装的网格蛋白笼。然而,肌醇六磷酸结合和网格蛋白笼结合均不影响AP3抑制PLD的能力。AP3也以低亲和力结合PI(4,5)P2。但PI(4,5)P2结合并非PLD抑制的原因,因为在不存在和存在PI(4,5)P2的情况下,AP3作为PLD抑制剂的效力和效果相似。一种细菌表达的融合蛋白,谷胱甘肽S - 转移酶 - AP3(GST - AP3),也以与脑AP3相同的效力抑制PLD。AP3的抑制作用似乎是AP3与PLD直接相互作用的结果,因为在体外结合试验中PLD结合了GST - AP3。使用包含各种AP3序列的GST融合蛋白,我们发现AP3从第290位脯氨酸到第320位赖氨酸的序列对于抑制和结合PLD都至关重要。AP3是一种突触特异性蛋白这一事实表明,AP3依赖的PLD抑制可能发挥仅限于突触小泡快速循环的调节作用。